Expression of interest (EOI) in receiving technical, regulatory and/or financial support to accelerate the commercialization of a quality assured product for Liposomal Amphotericin B (L-AmB).

WHO
Expression of interest (EOI) in receiving technical, regulatory and/or financial support to accelerate the commercialization of a quality assured product for Liposomal Amphotericin B (L-AmB). Request for EOI

Reference: Unitaid EOI – Liposomal Amphotericin B (L-AmB)
Beneficiary countries: Switzerland
Published on: 05-Jul-2022
Deadline on: 26-Jul-2022 00:00 (GMT 1.00)

Description

Unitaid is a global health agency engaged in finding innovative solutions to prevent, diagnose, and treat diseases more quickly, affordably and effectively, in low- and middle-income countries (LMICs). Its work includes funding initiatives to address major diseases such as HIV/AIDS, malaria, and tuberculosis, as well as HIV co-infections and co-morbidities.

This call for Expression of Interest (EOI) is issued to provide an opportunity for manufacturing companies with generic formulations of Liposomal Amphotericin B (L-AmB) in advanced stages of development and/or ready for commercialization for technical, regulatory and/or financial support to accelerate the commercialization of a quality assured product, to express their interest and provide relevant information which will help Unitaid to determine how to improve access to quality assured L-AmB in low- and middle-income countries (LMICs) at an affordable price.

We kindly invite you to participate in this EOI through the enclosed document, to be submitted to unitaid-proc@who.int by 26 July 2022, 17:00 (CET). Please note, any information submitted in response to this EOI is provided on a voluntary basis. Please also take note of disclaimer text on the EOI cover page.

We look forward to receiving your response.

Kind regards;

Unitaid Team